Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 92

1.

Impact of angiographic peri-stent contrast staining (PSS) on late adverse events after sirolimus-eluting stent implantation: an observation from the multicenter j-Cypher registry PSS substudy.

Imai M, Kimura T, Morimoto T, Saito N, Shiomi H, Kawaguchi R, Kan H, Mukawa H, Fujita H, Ishise T, Hayashi F, Nagao K, Take S, Taniguchi H, Sakamoto H, Yamane T, Shirota K, Tamekiyo H, Okamura T, Kishi K, Miyazaki S, Yamamoto S, Yamaji K, Kawasaki T, Taguchi E, Nakajima H, Kosedo I, Tada T, Kadota K, Mitsudo K.

Cardiovasc Interv Ther. 2014 Jul;29(3):226-36. doi: 10.1007/s12928-014-0248-6.

PMID:
24532230
2.

Incidence, risk factors, and clinical sequelae of angiographic peri-stent contrast staining after sirolimus-eluting stent implantation.

Imai M, Kadota K, Goto T, Fujii S, Yamamoto H, Fuku Y, Hosogi S, Hirono A, Tanaka H, Tada T, Morimoto T, Shiomi H, Kozuma K, Inoue K, Suzuki N, Kimura T, Mitsudo K.

Circulation. 2011 May 31;123(21):2382-91. doi: 10.1161/CIRCULATIONAHA.110.003459.

3.

Very late stent thrombosis and late target lesion revascularization after sirolimus-eluting stent implantation: five-year outcome of the j-Cypher Registry.

Kimura T, Morimoto T, Nakagawa Y, Kawai K, Miyazaki S, Muramatsu T, Shiode N, Namura M, Sone T, Oshima S, Nishikawa H, Hiasa Y, Hayashi Y, Nobuyoshi M, Mitudo K; j-Cypher Registry Investigators..

Circulation. 2012 Jan 31;125(4):584-91. doi: 10.1161/CIRCULATIONAHA.111.046599.

4.

Late adverse events after implantation of sirolimus-eluting stent and bare-metal stent: long-term (5-7 years) follow-up of the Coronary Revascularization Demonstrating Outcome study-Kyoto registry Cohort-2.

Natsuaki M, Morimoto T, Furukawa Y, Nakagawa Y, Kadota K, Yamaji K, Ando K, Shizuta S, Shiomi H, Tada T, Tazaki J, Kato Y, Hayano M, Abe M, Tamura T, Shirotani M, Miki S, Matsuda M, Takahashi M, Ishii K, Tanaka M, Aoyama T, Doi O, Hattori R, Kato M, Suwa S, Takizawa A, Takatsu Y, Shinoda E, Eizawa H, Takeda T, Lee JD, Inoko M, Ogawa H, Hamasaki S, Horie M, Nohara R, Kambara H, Fujiwara H, Mitsudo K, Nobuyoshi M, Kita T, Kimura T; CREDO-Kyoto PCI/CABG registry cohort-2 investigators..

Circ Cardiovasc Interv. 2014 Apr;7(2):168-79. doi: 10.1161/CIRCINTERVENTIONS.113.000987.

5.

Occurrence of late acquired peri-stent contrast staining: comparison between sirolimus-eluting stents and everolimus-eluting stents.

Fujiwara T, Sakakura K, Ako J, Wada H, Arao K, Sugawara Y, Momomura S.

Int Heart J. 2012;53(3):165-9.

6.

Sirolimus-eluting stent versus balloon angioplasty for sirolimus-eluting stent restenosis: Insights from the j-Cypher Registry.

Abe M, Kimura T, Morimoto T, Taniguchi T, Yamanaka F, Nakao K, Yagi N, Kokubu N, Kasahara Y, Kataoka Y, Otsuka Y, Kawamura A, Miyazaki S, Nakao K, Horiuchi K, Ito A, Hoshizaki H, Kawaguchi R, Setoguchi M, Inada T, Kishi K, Sakamoto H, Morioka N, Imai M, Shiomi H, Nonogi H, Mitsudo K; j-Cypher Registry Investigators..

Circulation. 2010 Jul 6;122(1):42-51. doi: 10.1161/CIRCULATIONAHA.109.905802.

7.

Safety and efficacy of the CYPHER Select Sirolimus-eluting stent in the "Real World"--clinical and angiographic results from the China CYPHER Select registry.

Gao RL, Xu B, Lu SZ, Chen JL, Han YL, Chen JZ, Gai LY, Ge JB, Wang WM, Du ZM, Huo Y, Wang LF, Gao W, Chen JY, He B, Jia GL, Yang ZJ, Cao KJ, Li WM, Shen WF, Wan Z, Huang DJ, Zhu GY; CCSR Investigators..

Int J Cardiol. 2008 Apr 25;125(3):339-46.

PMID:
17434617
8.

Comparison of 5-year outcomes in patients with and without unprotected left main coronary artery disease after treatment with sirolimus-eluting stents: insights from the j-Cypher registry.

Toyofuku M, Kimura T, Morimoto T, Hayashi Y, Shiode N, Nishikawa H, Nakao K, Shirota K, Kawai K, Hiasa Y, Kadota K, Nozaki Y, Isshiki T, Sone T, Mitsudo K; j-Cypher Registry Investigators..

JACC Cardiovasc Interv. 2013 Jul;6(7):654-63. doi: 10.1016/j.jcin.2013.03.015.

9.

Risk Factors and Clinical Impacts of Peri-Stent Contrast Staining After Second-Generation Drug-Eluting Stent Implantation.

Tokuda T, Yamawaki M, Mori S, Takimura H, Sakamoto Y, Kobayashi N, Araki M, Hirano K, Ito Y.

J Interv Cardiol. 2016 Apr;29(2):179-87. doi: 10.1111/joic.12282.

PMID:
26822952
10.

Sirolimus-eluting stent implantation for ostial right coronary artery lesions: five-year outcomes from the j-Cypher registry.

Ko E, Natsuaki M, Toyofuku M, Morimoto T, Matsumura Y, Oi M, Motohashi Y, Takahashi K, Kawase Y, Tanaka M, Kitada M, Yuzuki Y, Tamura T, Inoue K, Mitsudo K, Kimura T.

Cardiovasc Interv Ther. 2014 Jul;29(3):200-8. doi: 10.1007/s12928-013-0236-2.

PMID:
24390936
11.

Comparison of Long-Term Clinical Outcomes of Lesions Exhibiting Focal and Segmental Peri-Stent Contrast Staining.

Tokuda T, Yamawaki M, Takahara M, Mori S, Makino K, Honda Y, Takafuji H, Takama T, Tsutsumi M, Sakamoto Y, Takimura H, Kobayashi N, Araki M, Hirano K, Ito Y.

J Am Heart Assoc. 2016 Mar 18;5(3):e002878. doi: 10.1161/JAHA.115.002878.

12.

Peri-stent contrast staining and very late stent thrombosis after sirolimus-eluting stent implantation: an observation from the RESTART (REgistry of Stent Thrombosis for review And Re-evaluaTion) angiographic substudy.

Kozuma K, Kimura T, Suzuki N, Miyazawa A, Waseda K, Honda Y, Morimoto T, Aizawa T, Mitsudo K, Miyazaki S, Yamaguchi T, Isshiki T.

EuroIntervention. 2013 Nov;9(7):831-40. doi: 10.4244/EIJV9I7A137. Review.

13.

Safety of coronary sirolimus-eluting stents in daily clinical practice: one-year follow-up of the e-Cypher registry.

Urban P, Gershlick AH, Guagliumi G, Guyon P, Lotan C, Schofer J, Seth A, Sousa JE, Wijns W, Berge C, Deme M, Stoll HP; e-Cypher Investigators..

Circulation. 2006 Mar 21;113(11):1434-41.

14.

Late target lesion revascularization after implantation of sirolimus-eluting stent.

Hong MK, Mintz GS, Lee CW, Park DW, Lee SW, Kim YH, Jung IH, Kim SH, Cheong SS, Kim JJ, Park SW, Park SJ.

Catheter Cardiovasc Interv. 2008 Feb 15;71(3):299-303.

PMID:
17985380
15.

Firebird and cypher sirolimus-eluting stents and bare metal stents in treatment of very long coronary lesions.

Fan L, Chen LL, Lin CG, Peng YF, Zheng XC, Luo YK, Zhang FL, Chen JH, Yan XP, Huang ZR.

Chin Med J (Engl). 2008 Aug 20;121(16):1518-23.

PMID:
18982862
16.

Incidence and risk factors of late target lesion revascularization after sirolimus-eluting stent implantation (3-year follow-up of the j-Cypher Registry).

Nakagawa Y, Kimura T, Morimoto T, Nomura M, Saku K, Haruta S, Muramatsu T, Nobuyoshi M, Kadota K, Fujita H, Tatami R, Shiode N, Nishikawa H, Shibata Y, Miyazaki S, Murata Y, Honda T, Kawasaki T, Doi O, Hiasa Y, Hayashi Y, Matsuzaki M, Mitsudo K; j-Cypher Registry Investigators..

Am J Cardiol. 2010 Aug 1;106(3):329-36. doi: 10.1016/j.amjcard.2010.03.031.

PMID:
20643241
17.

Differential clinical outcomes after 1 year versus 5 years in a randomised comparison of zotarolimus-eluting and sirolimus-eluting coronary stents (the SORT OUT III study): a multicentre, open-label, randomised superiority trial.

Maeng M, Tilsted HH, Jensen LO, Krusell LR, Kaltoft A, Kelbæk H, Villadsen AB, Ravkilde J, Hansen KN, Christiansen EH, Aarøe J, Jensen JS, Kristensen SD, Bøtker HE, Thuesen L, Madsen M, Thayssen P, Sørensen HT, Lassen JF.

Lancet. 2014 Jun 14;383(9934):2047-56. doi: 10.1016/S0140-6736(14)60405-0.

PMID:
24631162
18.

Angiographic findings of everolimus-eluting as compared to sirolimus-eluting stents: angiographic sub-study from the Randomized Evaluation of Sirolimus-eluting versus Everolimus-eluting stent Trial (RESET).

Kozuma K, Kimura T, Kadota K, Suwa S, Kimura K, Iwabuchi M, Kawai K, Miyazawa A, Kawamura M, Nakao K, Asano R, Yamamoto T, Suzuki N, Aoki J, Kyono H, Nakazawa G, Tanabe K, Morino Y, Igarashi K.

Cardiovasc Interv Ther. 2013 Oct;28(4):344-51. doi: 10.1007/s12928-013-0179-7.

PMID:
23608784
19.

Sirolimus-eluting versus paclitaxel-eluting stents in diabetic and non-diabetic patients within sirolimus-eluting stent restenosis: results from the ISAR-DESIRE 2 trial.

Kufner S, Byrne RA, de Waha A, Schulz S, Joner M, Laugwitz KL, Kastrati A; Intracoronary Stenting and Angiographic Results: Drug Eluting Stents for In-Stent Restenosis 2, (ISAR-DESIRE 2) Investigators..

Cardiovasc Revasc Med. 2014 Mar;15(2):69-75. doi: 10.1016/j.carrev.2014.02.001.

PMID:
24684757
20.

Differential outcomes after sirolimus-eluting stent implantation: comparing on-label versus off-label patients in the 'real world'.

Jeremias A, Ruisi CP, Kirtane AJ, Lee T, Sylvia B, Pinto DS, Ho KK, Cutlip DE, Carrozza JP Jr, Cohen DJ.

Coron Artery Dis. 2008 Mar;19(2):111-5. doi: 10.1097/MCA.0b013e3282f34220.

PMID:
18300748

Supplemental Content

Support Center